Positive Data On Bayer/Algeta's Alpharadin Could Accelerate Filing Timeline
This article was originally published in Pharmaceutical Approvals Monthly
Bayer AG/Algeta ASA have halted early a Phase III trial evaluating their first-in-class targeted radioactive drug Alpharadin (radium 223-chloride) for the treatment of symptomatic bone metastases in advanced prostate cancer patients based on positive interim results.
You may also be interested in...
Some physicians may be concerned by the incidence of osteonecrosis of the jaw reported in pivotal hormone-resistant prostate cancer trial.
The launch of two drugs for metastatic prostate cancer this year – Dendreon Corp.'s Provenge (sipuleucel-T) and Sanofi-Aventis SA's Jevtana (cabazitaxel) – is shining a spotlight on an area of oncology that for many years was marked by a dearth of new treatment options.
Big Pharma still hot for castration-resistant prostate cancer drugs, despite Phase III burns in the past.